SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 78 filers reported holding SYROS PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 1.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $91,000 | -55.0% | 95,000 | -44.1% | 0.00% | -50.0% |
Q1 2022 | $202,000 | -63.5% | 170,000 | 0.0% | 0.00% | -60.0% |
Q4 2021 | $554,000 | +140.9% | 170,000 | +410.5% | 0.01% | +233.3% |
Q4 2019 | $230,000 | -33.5% | 33,300 | 0.0% | 0.00% | -40.0% |
Q3 2019 | $346,000 | +12.3% | 33,300 | 0.0% | 0.01% | +25.0% |
Q2 2019 | $308,000 | -54.0% | 33,300 | -54.6% | 0.00% | -50.0% |
Q1 2019 | $670,000 | +82.6% | 73,300 | +11.2% | 0.01% | +60.0% |
Q4 2018 | $367,000 | -64.1% | 65,900 | -23.3% | 0.01% | -50.0% |
Q3 2018 | $1,023,000 | +16.6% | 85,900 | 0.0% | 0.01% | +11.1% |
Q2 2018 | $877,000 | -32.2% | 85,900 | -13.8% | 0.01% | -35.7% |
Q1 2018 | $1,294,000 | – | 99,700 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 3,439,895 | $18,747,000 | 4.66% |
Bain Capital Life Sciences Investors, LLC | 5,785,036 | $31,528,000 | 2.07% |
Omega Fund Management, LLC | 2,274,831 | $12,398,000 | 1.40% |
Altium Capital Management LP | 1,076,942 | $5,869,000 | 1.36% |
Samsara BioCapital, LLC | 2,189,199 | $10,599,000 | 1.31% |
Sio Capital Management, LLC | 800,000 | $4,360,000 | 1.08% |
Flagship Pioneering Inc. | 2,938,494 | $16,015,000 | 0.20% |
EcoR1 Capital, LLC | 1,000,000 | $5,450,000 | 0.20% |
Artal Group S.A. | 1,700,000 | $9,265,000 | 0.19% |
ACT CAPITAL MANAGEMENT, LLC | 52,500 | $287,000 | 0.15% |